BI 473494

Drug Profile

BI 473494

Alternative Names: BI-473494

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim
  • Class Obesity therapies
  • Mechanism of Action Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 06 Nov 2017 Boehringer Ingelheim suspends patient enrolment in a phase I trial due to risk-benefit profile being re-evaluated for an unknown indication (In volunteers) in Germany (SC) (NCT03195088)
  • 27 Jul 2017 Phase-I clinical trials in Obesity (In volunteers) in Germany (SC) (NCT03195088)
  • 20 Jun 2017 Boehringer Ingelheim plans a phase I trial for an unknown indication (In volunteers) in Germany (SC) (NCT03195088)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top